[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-surgery":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,79,105,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605525","phase-4-evaluating-anti-obesity-medications-6-months-after-metabolic-surgery-100605525",false,"NCT07163650","Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery","A Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of Efsubaglutide Alfa in Patients Remaining Obese 6 Months After Metabolic Surgery","Inclusion Criteria:\n\n* 6 months after metabolic surgery\n* 18 years ≤ age ≤ 55 years\n* Body Mass Index (BMI) ≥ 28 kg\u002Fm\\^2\n* Voluntarily sign the informed consent form and agree to strictly adhere to the requirements and restrictions outlined in the informed consent form and this protocol throughout the entire study period.\n\nExclusion Criteria:\n\n* Subjects suspected by the investigator of having a potential allergy to the study drug or its components, or those with a history of allergic constitution;\n\n  * Use of any of the following drugs or treatments prior to screening:\n\n    ● Glucagon-like peptide-1 (GLP-1R) agonists within 3 months prior to screening\n\n    ● Use within 3 months prior to screening of any weight-affecting medications, including systemic corticosteroids, metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, etc.;\n\n    ● Use of weight-affecting herbal supplements, health products, or meal replacements within 3 months prior to screening;\n    * Use of weight-loss medications within 3 months prior to screening or currently using such medications, e.g., sibutramine hydrochloride, orlistat, phentermine, etc.;\n    * Participation in other clinical trials (receiving investigational drug treatment) within 3 months prior to screening.\n\n      ③ History or evidence of any of the following conditions prior to screening:\n    * History of depression; or history of severe psychiatric disorders such as schizophrenia, bipolar disorder, etc.;\n    * Uncontrolled hypertension at screening despite at least 4 weeks of antihypertensive medication, defined as systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg;\n    * History of malignancy at screening;\n    * History of cardiac disease at screening: acute myocardial infarction, unstable angina, post-coronary artery bypass grafting, post-percutaneous coronary intervention, severe arrhythmia;\n    * Hemorrhagic or ischemic stroke, or transient ischemic attack within 6 months prior to screening;\n    * History or family history of medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) type 2A or 2B at screening;\n    * History of acute or chronic pancreatitis, or pancreatic injury at screening;\n    * Presence of limb deformities or amputations preventing accurate measurement of height, weight, or other anthropometric parameters;\n    * Major or moderate surgery, severe trauma, or severe infection within 1 month prior to screening, deemed unsuitable for study participation by the investigator;\n    * History of suicidal tendencies or suicide attempts;\n    * Anticipated surgery during the study period;\n    * Participants testing positive for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or syphilis antibodies at screening;\n    * History of alcohol abuse within 1 month prior to screening, defined as average weekly alcohol intake exceeding 21 units for males or 14 units for females; ④ Presents clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening: - Second- or third-degree atrioventricular block - Long QT syndrome or QTcF \\> 450 ms - PR interval \\\u003C 120 ms or PR interval \\> 220 ms - QRS \\> 120 ms QRS duration \\>120ms, left or right bundle branch block, Wolff-Parkinson-White syndrome, or other severe arrhythmias requiring treatment;\n\n      * History of other risk factors for torsades de pointes, such as hypokalemia at screening, family history of long QT syndrome, or concomitant use of QT\u002FQTc-prolonging medications at screening; ⑥ Blood donation volume and\u002For blood loss ≥400 mL within 3 months prior to screening, or hemoglobin \\\u003C110 g\u002FL (males) or \\\u003C100 g\u002FL (females); ⑦ Presence of any other factors deemed by the investigator to potentially affect the efficacy or safety evaluation of this study, rendering the subject unsuitable for participation.","ALL","18 Years","55 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.",[27,28,29],"Obesity","Weight Loss","Metabolic Surgery",[31,32,33,34,35],"obesity","BMI","GLP-1 receptor agonist","Efsubaglutide Alfa","Metabolic surgery","RECRUITING","2026-01-25",{"date":39,"type":40},"2026-01-27","ACTUAL",{"date":42,"type":40},"2025-09-16",{"date":44,"type":21},"2027-02-28",{"name":46,"class":47},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100574246","conventional-vs-tailored-limb-lengths-in-laparoscopic-roux-en-y-gastric-bypass-surgery-100574246","NCT06756789","Conventional Vs Tailored Limb Lengths in Laparoscopic Roux-en Y Gastric Bypass Surgery","Randomized Controlled Trial on Conventional Vs Tailored Limb Lengths in Laparoscopic Roux-en Y Gastric Bypass Surgery","TAILO-R-YGB","Inclusion Criteria:\n\n1. Age: 18-65 years\n2. Body Mass Index (BMI):\n\n   BMI ≥ 40 kg\u002Fm² or BMI ≥ 35 kg\u002Fm² with at least one obesity-related comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnea).\n3. ASA - less than or equal to 3\n4. Informed Consent: Ability and willingness to provide written informed consent and comply with procedures.\n5. Previous Weight Loss Attempts: Documentation of previous attempts at weight loss through diet, exercise, or medical management.\n\nExclusion Criteria:\n\n1. Previous Bariatric Surgery: Prior bariatric or major gastrointestinal surgery that might affect the outcome of RYGB.\n2. Severe Cardiopulmonary Conditions: Significant cardiac or pulmonary conditions that pose a high surgical risk (e.g., severe congestive heart failure, severe chronic obstructive pulmonary disease).\n3. Uncontrolled Psychiatric Disorders: Severe psychiatric illness or substance abuse issues that are not well-controlled, including eating disorders.\n4. Pregnancy: Current pregnancy or plans to become pregnant within 12 months post-surgery.\n5. Malignancy: Active malignancy or history of malignancy requiring treatment in the past 5 years (excluding non-melanoma skin cancer).\n6. Severe Liver Disease: Cirrhosis or significant liver dysfunction (e.g., Child-Pugh B or C).\n7. Inability to Comply: Patients who are unable or unwilling to comply with the postoperative follow-up schedule and dietary requirements.\n8. Chronic Use of Medications: Chronic use of medications known to affect weight or metabolism significantly, such as corticosteroids or antipsychotics.\n9. Other Medical Conditions: Any other medical condition or surgical finding that, in the opinion of the investigators, would make the patient unsuitable for the study.","65 Years",{"count":59,"type":21},40,[61],"NA","The study aims to investigate whether tailoring limb lengths based on the 1\u002F3rd and 2\u002F3rd concept improves clinical outcomes in Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) surgery compared to conventional limb lengths. In this study, two groups were described, first group involves patients who will undergo Lap RYGB with conventional limb lengths of 75cms and 125cms, while the second group is given tailored limb lengths according to the total small bowel length. In the follow up period, Total percentage weight loss, improvement in BMI along with the remission of co-morbidities were also assessed.",[27,64,65,29,66],"Metabolic Disease","Bariatric Surgery Candidate","RYGB",[27,66,68,35,69],"Bariatric surgery","Metabolic syndrome","2024-12-30",{"date":72,"type":40},"2025-01-03",{"date":74,"type":40},"2024-04-01",{"date":76,"type":21},"2025-12",{"name":78,"class":47},"GEM Hospital & Research Center",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100537225","chinese-obesity-and-metabolic-surgery-database-comes-database-100537225","NCT06275061","Chinese Obesity and MEtabolic Surgery Database (COMES Database)","Chinese Obesity and MEtabolic Surgery Database","COMES","Inclusion Criteria:\n\n* Patients diagnosed as obesity undergoing metabolic and bariatric surgery.\n\nExclusion Criteria:\n\n* Patients treated by non-surgical modalities.",true,{"count":89,"type":21},1000000,"30 Years","OBSERVATIONAL","The purpose of the Chinese Obesity and MEtabolic Surgery Database (COMES Database) is to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population.",[27,29,94,28],"Bariatric Surgery",[27,29,94,28],"2024-02-21",{"date":98,"type":40},"2024-02-23",{"date":100,"type":40},"2020-05-01",{"date":102,"type":21},"2040-12-31",{"name":104,"class":47},"Jinan University Guangzhou",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":91,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100325721","beijing-friendship-hospital-metabolic-surgery-database-100325721","NCT03520699","Beijing Friendship Hospital Metabolic Surgery Database","Beijing Friendship Hospital Metabolic Surgery Clinical Database","Inclusion Criteria:\n\n* be able to receive metabolic surgery (LSG or LRYGB)\n\nExclusion Criteria:\n\n* can not be able to understand and willing to participate in this registry with signature",{"count":113,"type":21},3000,"3 Months","Metabolic surgery, as a recognition treatment option for patients with clinical morbid obesity, is gaining increasing appreciation. In addition to substantial weight loss, emerging studies have highlighted that metabolic surgery can substantially ameliorate obesity-related metabolic diseases, including but not limited to type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea-hypopnea syndrome (OSAHS) and polycystic ovary syndrome (PCOS)in severely obese patients. However, further investigations with larger sample size and longer observation time still needed to clarity the efficacy and safety of metabolic surgery in Chinese patients with obesity and encouraging future research in this field.",[29],[118,119],"metabolic surgery","metabolic disease","2019-09-09",{"date":122,"type":40},"2019-09-10",{"date":124,"type":40},"2017-12-01",{"date":126,"type":21},"2028-12-31",{"name":128,"class":47},"Beijing Friendship Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":136,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":48},"100321646","five-year-outcome-of-laparoscopic-gastric-sleeve-100321646","NCT03467581","Five-year Outcome of Laparoscopic Gastric Sleeve","Five-year Outcome of Laparoscopic Gastric Sleeve, Resolution of Comorbidities and Risk for Cumulative Nutritional Deficiencies.","Inclusion Criteria:\n\n* The criteria for bariatric surgery: BMI of \\>40, or \\>35 with certain obesity related comorbidities\n\nExclusion Criteria:\n\n* Patients who did not fill the inclusion criteria",{"count":137,"type":21},500,"The aim of this study is to evaluate the long-term (5-year follow-up) results of laparoscopic gastric sleeve (LGS) in terms of weight loss and obesity related comorbidities, as well as the risk factors associated with postoperative nutritional deficiencies.",[140,29],"Bariatric Surgeries",[142],"gastric sleeve","2018-03-09",{"date":145,"type":40},"2018-03-16",{"date":147,"type":40},"2008-10-08",{"date":126,"type":21},{"name":150,"class":47},"Tartu University Hospital"]